Keyphrases
Phase 1 Trial
100%
Recurrent Glioblastoma
100%
Ultrasound Device
100%
Albumin Paclitaxel
100%
Blood-brain Barrier Opening
100%
Dose Level
30%
Encephalopathy
30%
Blood-brain Barrier
20%
First Cycle
20%
Pharmacokinetic Analysis
20%
Carboplatin
20%
Skull
20%
Dose-limiting Toxicity
20%
Pharmacokinetics
10%
Headache
10%
Hypertension
10%
National Institutes of Health
10%
Brain Regions
10%
Peripheral Neuropathy
10%
Phase II Study
10%
Phase II Trial
10%
Phase 1 Clinical Trial
10%
Accruals
10%
National Cancer Institute
10%
Imaging Analysis
10%
Family Foundations
10%
Microbubbles
10%
Cytotoxic Drugs
10%
Dose Escalation
10%
Neutropenia
10%
3-cycle
10%
Treatment-related Adverse Events
10%
Concomitant Administration
10%
Leukopenia
10%
Neurological Deficit
10%
Tumor Resection
10%
Treatment-related Mortality
10%
Tumor Diameter
10%
Low-intensity Pulsed Ultrasound (LIPUS)
10%
Carboplatin-paclitaxel
10%
Karnofsky Performance Status
10%
Per-protocol
10%
Paclitaxel Chemotherapy
10%
Grade 12
10%
Medicine and Dentistry
Glioblastoma
100%
Blood Brain Barrier
100%
Paclitaxel
100%
Carboplatin
30%
Pharmacokinetics
30%
Brain Disease
30%
Magnetic Resonance Imaging
10%
Neoplasm
10%
Adverse Event
10%
Neutropenia
10%
Infusion
10%
Low Drug Dose
10%
Headache
10%
Leukopenia
10%
Malignant Neoplasm
10%
Brain Region
10%
Cancer Surgery
10%
Neuropathy
10%
Karnofsky Performance Status
10%
Low-Intensity Pulsed Ultrasound
10%
Clinical Trial
10%
Cytotoxic Agent
10%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
100%
Paclitaxel
100%
Blood-Brain Barrier
100%
Brain Disease
30%
Carboplatin
30%
Pharmacokinetics
30%
Neoplasm
20%
Chemotherapy
10%
Clinical Trial
10%
Malignant Neoplasm
10%
Headache
10%
Adverse Event
10%
Neuropathy
10%
Leukopenia
10%
Neutropenia
10%
Cytotoxic Agent
10%
Neuroscience
Paclitaxel
100%
Blood Brain Barrier
100%
Carboplatin
30%
Brain Disease
30%
Pharmacokinetics
30%
Skull
20%
Hypertension
10%
Magnetic Resonance Imaging
10%
Headache
10%
Neuropathy
10%